Litcius/Paper detail

Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study

Taigo Kato, Kazutoshi Fujita, Takafumi Minami, Akira Nagahara, Yujiro Hyashi, Wataru Nakata, Kyosuke Matsuzaki, Kosuke Nakano, Koji Hatano, Atsunari Kawashima, Ryoichi Imamura, Shingo Takada, Kensaku Nishimura, Masao Tsujihata, Tetsuya Takao, Yasutomo Nakai, Masashi Nakayama, Kazuo Nishimura, Motohide Uemura, Hirotsugu Uemura, Norio Nonomura

2022International Journal of Clinical Oncology22 citationsDOI

Topics & Concepts

MedicineIpilimumabNivolumabRenal cell carcinomaNephrectomyInternal medicineSurgical oncologyRetrospective cohort studyClinical trialResponse Evaluation Criteria in Solid TumorsOncologySurgeryPhases of clinical researchCancerKidneyImmunotherapyRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study | Litcius